- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
Patent holdings for IPC class C07K 14/715
Total number of patents in this class: 2932
10-year publication summary
|
115
|
206
|
183
|
228
|
273
|
266
|
321
|
295
|
253
|
143
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 4786 |
110 |
| Altor BioScience, LLC | 80 |
58 |
| Xencor, Inc. | 411 |
43 |
| Immunitybio, Inc. | 509 |
40 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 3010 |
38 |
| The Board of Trustees of the Leland Stanford Junior University | 6687 |
35 |
| The Trustees of the University of Pennsylvania | 4423 |
35 |
| Vib VZW | 912 |
28 |
| Synthekine, Inc. | 118 |
28 |
| National University of Singapore | 2595 |
27 |
| The Regents of the University of California | 20815 |
25 |
| Cytune Pharma | 40 |
25 |
| Dana-Farber Cancer Institute, Inc. | 2666 |
25 |
| Universiteit Gent | 1411 |
25 |
| Amgen Inc. | 4440 |
24 |
| FATE Therapeutics, Inc. | 235 |
24 |
| Singapore Health Services Pte Ltd | 495 |
24 |
| Autolus Limited | 266 |
23 |
| Novartis AG | 10173 |
21 |
| Bristol-myers Squibb Company | 4757 |
19 |
| Other owners | 2255 |